AdamJacobSchoenfeldMD

Thoracic Cancer

Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

Overview of Dr. Schoenfeld

Dr. Adam Schoenfeld is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Sloan Kettering Cancer Center. He received his medical degree from University of California (San Francisco) School of Medicine and has been in practice 3 years. He is one of 493 doctors at Memorial Sloan Kettering Cancer Center and one of 493 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 60 publications and over 500 citings.

Office
530 East 74th Street
New York, NY 10021
Book by Phone+1(828) 634-7617

Education & Training

University of California (San Francisco)Residency, Internal Medicine, 2014 - 2017
University of California San Francisco School of MedicineClass of 2014, AOA

Certifications & Licensure

CA State Medical License 2016 - Present
FL State Medical License 2021 - Present
NJ State Medical License 2020 - 2025
NY State Medical License 2017 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Kaiser Permanente Medical Student Scholarship Award Kaiser Permanente, 2013
New England Journal of Medicine Scholar New England Journal of Medicine, 2012
Phi Beta Kappa Society Member Dartmouth College, 2009

Publications & Presentations

PubMed

101 citations
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.
Julie R Brahmer, Jong-Seok Lee, Tudor-Eliade Ciuleanu, Reyes Bernabe Caro, Makoto Nishio
Journal of Clinical Oncology. 2023-02-20
233 citations
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
Adam J. Schoenfeld, Kathryn C. Arbour, Hira Rizvi, A. Iqbal, Shirish M. Gadgeel
Annals of Oncology. 2019-05-01
48 citations
Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors.
Amin H Nassar, Elio Adib, Sarah Abou Alaiwi, Talal El Zarif, Stefan Groha
Cancer Cell. 2022-10-10

Journal Articles

Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients with Metastatic EGFR-Mutant Lung Cancers
Helena A Yu, Adam J Schoenfeld, Jamie E Chaft, Gregory J Riely, JAMA Oncology
Synthesis, Structure, Dynamics, and Selective Methylation of Platinum and Palladium Diphosphametallacyclobutane Complexes
Chapp TW, Schoenfeld A, Sanderson MD, Chang C, Glueck DS, Golen J, Moore C, Rheingold A, Organometallics, 2012
Effects of Linker Length on the Rate and Selectivity of Platinum-Catalyzed Asymmetric Alkylation of the Bis(isitylphosphino)alkanes IsHP(CH2)nPHIs (is = 2,4,6-(i-pr)3C...
Chapp TW, Schoenfeld A, Glueck DS, Organometallics, 2010

Abstracts/Posters

The CNS Germinoma Experience at UCSF from 1980 to 2010
Schoenfeld A, Molinaro A, Banerjee A, Haas-Kogan D, Mueller S, 3rd International CNS Germ Cell Tumour Symposium, Cambridge, England, 2013

Lectures

Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers.
2019 ASCO Annual Meeting - 6/1/2019